Serious but rare adverse effects include: Acute pancreatitis (patients should be advised to seek immediate medical attention for severe, persistent abdominal pain) Gallbladder disease, including cholecystitis and cholelithiasis Acute kidney injury, particularly in the context of dehydration from gastrointestinal side effects Hypoglycaemia, especially when used alongside other glucose-lowering medications Thyroid C-cell tumours (observed in rodent studies
Phase II data showed 24.2% body weight reduction at 48 weeks
Dans les heures qui suivent un repas, on observe une augmentation de la libration dinsuline, comparable avec ou sans smaglutide
Common triggers include alcohol, chocolate, caffeine, fatty foods or peppermint
Patients should be monitored for allergic or anaphylactoid reactions
En palabras del Javier Ampudia , endocrinlogo del Hospital Universitario Clnico de Valencia, todos estos estudios posicionan a orforglipron como una excelente alternativa teraputica en personas con diabetes tipo 2 y obesidad, a tener muy en cuenta incluso desde las fases iniciales de la enfermedad
